Antibiotic resistance is on the rise. According to the Centers for Disease Control and Prevention (CDC), at least 2 million people are infected with antibiotic-resistant bacteria in the U.S. each year, and 23,000 people die as a result. OpGen is uniquely positioned to tackle this rising crisis.
The power of informatics and genomic analysis
OpGen harnesses the power of informatics and genomic analysis to detect and track transmissions of antibiotic-resistant microbes. With our large and ever-growing Acuitas Lighthouse database, we analyze pathogens from around the world, and are developing real-time antibiotic guidance for caregivers.
At OpGen, we seek to use precision medicine to manage infectious disease, changing the paradigm of care.
To develop Acuitas Lighthouse, OpGen evaluated more than 250,000 antibiotic resistant isolates from Merck’s SMART surveillance study. We phenotyped approximately 10,000 isolates for antimicrobial susceptibility, testing 29 different antibiotics, and then sequenced the isolates’ DNA to identify 200 unique resistance genes. From that genetic data, OpGen developed statistical models to predict resistance—one of the core features of Acuitas Lighthouse.
Our business model
Validated, Disruptive Technology
Collaborations and partnerships with NY Dept. of Health, Merck, QIAGEN and Thermo Fisher
SIGNIFICANT MARKET OPPORTUNITY
Working to address a $2B global market in need of novel solutions
ADDRESSING MAJOR GLOBAL CRISIS
Multi-drug resistance causes $20B in excess direct healthcare costs and 700,000 deaths annually
BUILDING COMMERCIAL MOMENTUM
Meeting key commercial milestones including regulatory approvals
Management has proven track record of value creation for diagnostic, genomic, and pharma companies